Materials and measurements
The 1 H and 13 C NMR spectra were recorded on a Bruker Avance DPX300 with tetramethylsilane as an internal standard. All NMR spectra were obtained using CDCl 3 as the solvent unless otherwise noted. GC-Mass was carried out on a 6890N GC-Agilent 5973N.
HPLC was carried US Agilent 1100. Mass spectra were obtained with a VG-ZAB-HS mass spectrometer. Mass spectra data are reported in mass to charge units (m/z). High-resolution mass spectra (HRMS) were recorded in ESI mode using Bruker Apex IV FTMS. Optical rotations were obtained from a Perkin Elmer 241MC polarimeter. Commercially available compounds were used in this work without further purification. The solvent tetrahydrofuran (THF) and benzene was dried by distillation from sodium and benzophenone. The Physiology and Biochemistry.
Synthesis of iso-PhABA 4
1.2.1 2,2-Dimethyl-3,4-dihydro-2H -naphthalen-1-one (6) To a stirred suspension of NaH (11.6g, 334mmol, 70% in oil) in THF (25mL) in a 500mL round bottomed flask, was added, 1-tetralone 5 (10.0 g, 69mmol) dissolved in dry THF (20mL). After stirring the mixture for 10 min at r.t., methyl iodide (11.1mL, 178mmol) was added slowly. The mixture was then heated to 40℃ for 30min, and stirring continued at r.t. 3h.
The reaction was quenched by addition of water (slowly and dropwise). The mixture then extracted with ethyl acetate (3×100mL), washed with water (2×100mL) and dried over anhydrous Na 2 SO 4 . Evaporation of the solvent yielded a brown oil. The residue was subjected to silica gel chromatography using PE and EtOAc (10:1) as eluant to afford 2,2-dimethyl-1-tetralone 6 (11.3g, 95% 
To a stirred solution of
.3mmol) in dry THF was cooled to 0℃and Red-Al (2.8mL, 9.9mmol, 3.6M in toluene) added dropwise via syringe. The reaction mixture was stirred at r.t.
for a further 3h. The reaction was quenched by slow addition of water (5mL) and extracted with diethyl ether (3×30mL). The organic phase was washed with water (2×20mL) and dried over anhydrous Na 2 SO 4 and filtered, filtrate concentrated under reduced pressure. The residue was subjected to silica gel chromatography using PE and EtOAc (1:1) as eluant to afford 
Bioassays.
The bioassays activities of the synthesized compounds were tested using our previously reported methods 1 .
3. Receptor binding assay.
Protein expression and purification
PYR1 and PYL1 to PYL13 were subcloned from the Arabidopsis thaliana cDNA library using standard PCR-based protocol. The fragments were inserted into the pET-28a vector or pGEX-4T-2 vector, in which the thrombin recognition site was replaced by TEV recognition 
Phosphatase activity assay
The phosphatase activity was measured by the serine-threonine phosphatase assay system (Promega V2460 kit). Each reaction was performed in a 45 L reaction buffer (20mMHepes pH 7.5, 150mM NaCl and 5mM MgCl 2 ) containing 3M HAB1, 5M PYLs protein and (+)/(-)-iso-PhABA of 10M concentration if required. After 30min at room temperature, 5L
phosphorylated peptide substrate supplied with the Promega kit was added into the reaction system at 30°C for 25min. And then the reaction was terminated by addition of 50L molybdate dye/additive mixture, and the absorbance at 620nm was measured 30min later. The OD 620 value of the reaction without HAB1 was set as baseline while the phosphatase activity S7 of the reaction without PYLs was set as 100% for HAB1. Each reaction was repeated at least three times and the error bars indicated standard deviations.
MST
The microscalethermophoresis (MST) method has been described in detailelsewhere [2] . 
Crystallization and data collection
To get the PYL10-(+)-iso-PhABA complex crystals, (+)-iso-PhABA was mixed with purified PYL10 at 5:1 ratio and then incubated on ice overnight. The mixture was concentrated to about 10mg/mL.The crystallization screen conditions were from commercial kits (Hampton Research and Emerald Biosystems) and some self-made products. Initial trails were performed by sitting-drop vapor diffusion method at 20℃ and 4℃, respectively.
Crystallization-solution droplet was comprised of 1.0μL each reservoir solution and 1.0μL
freshly purified target protein complex, which was equilibrated against 100μL each reservoir solution. The complex crystals appeared in a well solution contained 10% iso-propanol, 0.1M Na Hepes pH 7.5, 20% PEG4000. The crystal was transferred into well solution containing 20% glycol as cryo-protectant solution and flash-cooled in liquid nitrogen before collecting data.
To get the PYL10-(-)-iso-PhABA complex crystals, purified apo-PYL10 fragment was concentrated to about 10mg/mL for screening crystals. Apo-PYL10 native crystal appeared in the reservoir solution contained 25% PEG3350, 0.1MTris-HCl pH 8. All the crystal data were collected at KEK beamline NE3A, SSRF beamline BL17U and BSRF beamline 1W2B. All the data were integrated and scaled with the HKL2000 suite of programs 3 . Data collection statistics are summarized in Table 1 . 
Structure determination
Using apo-PYL10 structure (PDB code: 3UQH) 4 as the search model, molecular replacement solutions of the PYL10-(+)/(-)-iso-PhABA were found using MOLREP 5 . The model and ligands were built manually in the program COOTS9 the CCP4 package 7 . We used the program REFMAC5 8 to refine the structure. Structure refinement statistics are shown in Table 1 .
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